CLLS Stock Analysis: Buy, Sell, or Hold?
CLLS - Cellectis S.A. American Depositary Shares
$4.04
0.14 (3.59%)
▲
5d:
+3.86%
30d:
+19.53%
90d:
+6.6%
BUY
MODERATE Confidence
Analysis Updated: Apr 30, 2026 12:00 AM ET
Earnings: May 11, 2026
9d
Get Alerted When CLLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CLLS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CLLS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CLLS is currently trading at $4.04, which is considered slightly high relative to its 30-day fair value range of $3.32 to $4.10.
Technical Outlook: Technically, CLLS is in a downtrend. Immediate support is located at $3.73, while resistance sits at $4.50. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.25 (+85.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CLLS is in a downtrend. Immediate support is located at $3.73, while resistance sits at $4.50. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.25 (+85.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.32 -
$4.10
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.1%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading 85.9% below Wall St target ($7.25)
Trading Range Analysis
30-Day Trading Range
$3.32 -
$4.10
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.73
Resistance Level
$4.50
Current Trend
Downtrend
Technical data as of
Apr 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.82
Wall Street Target
$7.25
(+85.9%)
Revenue Growth (YoY)
-19.5%
Profit Margin
-84.9%
Share & Embed Analysis
Last updated: May 01, 2026 10:29 AM ET
Data refreshes hourly during market hours. Next update: 11:29 AM
Data refreshes hourly during market hours. Next update: 11:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$548 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 55 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$878 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$226 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 46 HOLD |
